Katie Simas’ Post

How do we position regional and community sites for success and mitigate risks for sponsors? In our new Oncology report, Parexel’s Karen McIntyre and Angela Hirst weigh in on why the traditional approach to site selection in oncology has created bottlenecks at major centers, potentially limiting patient access to life-changing therapies. That’s why Parexel is bridging the gap by partnering with regional and community sites while still ensuring the high-quality standards of academic centers. Find out how: https://lnkd.in/eptD_mkM #ParexelBiotech #ResearchSites #Oncology #NovelInsights

How do we position regional and community sites for success and mitigate risks for sponsors? In our new Oncology report, Parexel’s Karen McIntyre and Angela Hirst weigh in on why the traditional approach to site selection in oncology has created bottlenecks at major centers, potentially limiting patient access to life-changing therapies. That’s why Parexel is bridging the gap by partnering with regional and community sites while still ensuring the high-quality standards of academic centers. Find out how: https://lnkd.in/gXZSaZe2 #ParexelBiotech #ResearchSites #Oncology #NovelInsights

How do we position regional and community sites for success and mitigate risks for sponsors? In our new Oncology report, Parexel’s Karen McIntyre and Angela Hirst weigh in on why the traditional approach to site selection in oncology has created bottlenecks at major centers, potentially limiting patient access to life-changing therapies. That’s why Parexel is bridging the gap by partnering with regional and community sites while still ensuring the high-quality standards of academic centers. Find out how: https://lnkd.in/dXTCpAsV #ParexelBiotech #ResearchSites #Oncology #NovelInsights

How do we position regional and community sites for success and mitigate risks for sponsors? In our new Oncology report, Parexel’s Karen McIntyre and Angela Hirst weigh in on why the traditional approach to site selection in oncology has created bottlenecks at major centers, potentially limiting patient access to life-changing therapies. That’s why Parexel is bridging the gap by partnering with regional and community sites while still ensuring the high-quality standards of academic centers. Find out how: https://lnkd.in/d6f-Bfnk #ParexelBiotech #ResearchSites #Oncology #NovelInsights

How do we position regional and community sites for success and mitigate risks for sponsors? In our new Oncology report, Parexel’s Karen McIntyre and Angela Hirst weigh in on why the traditional approach to site selection in oncology has created bottlenecks at major centers, potentially limiting patient access to life-changing therapies. That’s why Parexel is bridging the gap by partnering with regional and community sites while still ensuring the high-quality standards of academic centers. Find out how: https://lnkd.in/eqefFjJ2 #ParexelBiotech #ResearchSites #Oncology #NovelInsights

How do we position regional and community sites for success and mitigate risks for sponsors? In our new Oncology report, Parexel’s Karen McIntyre and Angela Hirst weigh in on why the traditional approach to site selection in oncology has created bottlenecks at major centers, potentially limiting patient access to life-changing therapies. That’s why Parexel is bridging the gap by partnering with regional and community sites while still ensuring the high-quality standards of academic centers. Find out how: https://lnkd.in/e62TQYRb #ParexelBiotech #ResearchSites #Oncology #NovelInsights

How do we position regional and community sites for success and mitigate risks for sponsors? In our new Oncology report, Parexel’s Karen McIntyre and Angela Hirst weigh in on why the traditional approach to site selection in oncology has created bottlenecks at major centers, potentially limiting patient access to life-changing therapies. That’s why Parexel is bridging the gap by partnering with regional and community sites while still ensuring the high-quality standards of academic centers. Find out how: https://lnkd.in/e2K8UVWr #ParexelBiotech #ResearchSites #Oncology #NovelInsights

How do we position regional and community sites for success and mitigate risks for sponsors? In our new Oncology report, Parexel’s Karen McIntyre and Angela Hirst weigh in on why the traditional approach to site selection in oncology has created bottlenecks at major centers, potentially limiting patient access to life-changing therapies. That’s why Parexel is bridging the gap by partnering with regional and community sites while still ensuring the high-quality standards of academic centers. Find out how: https://lnkd.in/e2K8UVWr #ParexelBiotech #ResearchSites #Oncology #NovelInsights

How do we position regional and community sites for success and mitigate risks for sponsors? In our new Oncology report, Parexel’s Karen McIntyre and Angela Hirst weigh in on why the traditional approach to site selection in oncology has created bottlenecks at major centers, potentially limiting patient access to life-changing therapies. That’s why Parexel is bridging the gap by partnering with regional and community sites while still ensuring the high-quality standards of academic centers. Find out how: https://lnkd.in/eB3zih2B #ParexelBiotech #ResearchSites #Oncology #NovelInsights

How do we position regional and community sites for success and mitigate risks for sponsors? In our new Oncology report, Parexel’s Karen McIntyre and Angela Hirst weigh in on why the traditional approach to site selection in oncology has created bottlenecks at major centers, potentially limiting patient access to life-changing therapies. That’s why Parexel is bridging the gap by partnering with regional and community sites while still ensuring the high-quality standards of academic centers. Find out how: https://lnkd.in/djpgNkxB #ParexelBiotech #ResearchSites #Oncology #NovelInsights